Claire Jansson-Knodell

Dr. Claire Jansson-Knodell

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2023 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
CJClaire Jansson-Knodell
Claire Jansson-Knodell
MCMelis G Celdir
Melis G Celdir
IHIsabel A Hujoel
Isabel A Hujoel
RLRuishen Lyu
Ruishen Lyu
DGDavid Gardinier
David Gardinier
ARAlberto Rubio‐Tapia
Alberto Rubio‐Tapia

20 January 2023 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
CJClaire Jansson-Knodell
Claire Jansson-Knodell
MWMattie White
Mattie White
CLCarolyn Lockett
Carolyn Lockett
HXHuiping Xu
Huiping Xu
ARAlberto Rubio-Tapia
Alberto Rubio-Tapia
ASAndrea Shin
Andrea Shin

1 March 2021 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
CJClaire Jansson-Knodell
Claire Jansson-Knodell
ARAlberto Rubio-Tapia
Alberto Rubio-Tapia

11 October 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
RKRidhima Kaul
Ridhima Kaul
CJClaire Jansson-Knodell
Claire Jansson-Knodell
MSMadison L. Simons
Madison L. Simons
KWKendra Weekley
Kendra Weekley
DGDavid Gardinier
David Gardinier
ARAlberto Rubio-Tapia
Alberto Rubio-Tapia
Celiac disease (CeD) is an autoimmune disorder where adherence to a lifelong gluten-free diet (GFD) is the only available treatment. While this approach is rather effective, some patients experience ongoing symptoms, and this factor, along with the rigidity of the GFD, may predispose some to disordered eating behaviors, including Avoidant/Restrictive Food Intake Disorder (ARFID). ARFID is characterized by persistent food avoidance that is not driven by body image concerns, resulting in nutritional, psychological, and social impairment. This scoping literature review explores the emerging intersection between ARFID and CeD, examining prevalence, pathophysiology, clinical features, complications, and management strategies. Recent studies report that 14–57% of individuals with CeD may meet the criteria for ARFID, depending on the population and screening tools used. Factors contributing to ARFID in CeD may include ongoing gastrointestinal symptoms, anxiety over gluten exposure, negative conditioned responses to food, social challenges related to GFD adherence, and psychiatric co-morbidities. ARFID in CeD is associated with worsened nutritional deficiencies, anxiety, depression, and impaired social functioning, making the diagnosis of ARFID challenging due to symptom overlap with CeD and other psychiatric conditions. Management requires a multidisciplinary approach, including medical, nutritional, and psychological interventions. Routine screening, early intervention, and integrated care models may improve outcomes and quality of life.

25 July 2019 in Hepatology
Verified
Journal Article
Open access
PDF file
CJClaire Jansson-Knodell
Claire Jansson-Knodell
SGSamer Gawrieh
Samer Gawrieh
AMAdam McIntyre
Adam McIntyre
TLTiebing Liang
Tiebing Liang
RHRobert Hegele
Robert Hegele
NCNaga Chalasani
Naga Chalasani
Patients with homozygous familial hypobetalipoproteinemia (FHBL) may develop non‐alcoholic steatohepatitis (NASH) and fibrosis; heterozygous FHBL is typically not associated with clinically significant nonalcoholic fatty liver disease (NAFLD).1

1 May 2021 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
CJClaire Jansson-Knodell
Claire Jansson-Knodell
RMRichard S. Mangus
Richard S. Mangus
AGAshley C. Gilmore
Ashley C. Gilmore